TESARO (TSRO) to Offer $300M in Common Stock

TESARO (TSRO) Prices 4.65M Common Stock Offering at $81/Share

TESARO, Inc. (Nasdaq: TSRO) announced that it has priced an underwritten public offering of an aggregate of 4,650,000 shares of its common stock at an offering price to the public of $81.00 per share. The gross proceeds from the offering will be approximately $376.7 million. In addition, TESARO has granted the underwriters an option to purchase up to an additional $56.5 million of... More

TESARO (TSRO) Niraparib Data Suggests PARP Inhibitors Will be Important - Stifel (CLVS) (AZN)

Clovis Oncology, Inc. (Nasdaq: CLVS) shares are trading strong Wednesday following phase 3 NOVA data from TESARO, Inc. (Nasdaq: TSRO), as announced... More

Tesaro (TSRO) Valuation Range Lifted to $122-$132 at Wells Fargo

Wells Fargo analyst Jim Birchenough raised his valuation range on Outperform-rated Tesaro (NASDAQ: TSRO) to $122-$132 from $88-495 following today's positive NOVA results.

For an analyst ratings summary and ratings history on Tesaro click here. For more ratings news on Tesaro click here.

Shares of Tesaro closed at $37.21 yesterday.

TESARO (TSRO) Nearly Doubles as Phase 3 NOVA Trial of Niraparib Achieves Primary Endpoint

TESARO (NASDAQ: TSRO) is surging 88% in pre-open trade after the company announced that the Phase 3 NOVA trial of niraparib successfully achieved its primary... More

TESARO (TSRO) Phase 3 NOVA Trial of Niraparib Achieves Primary Endpoint

TESARO, Inc. (NASDAQ: TSRO) announced that the Phase 3 NOVA trial of niraparib successfully achieved its primary endpoint of progression-free survival (PFS). This trial demonstrated that niraparib significantly prolonged PFS compared to control among patients who are germline BRCA mutation (gBRCAmut) carriers, among patients who are not germline BRCA mutation (non-gBRCAmut) carriers but who have homologous recombination deficient (HRD) tumors as determined by the Myriad myChoice® HRD test, and overall in patients who are not germline BRCA mutation carriers.

We are extremely grateful to the patients, caregivers, and investigators who participated in... More